15 Posts From ASCO24 Day 3 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May 31st to June 4th 2024.
Our team at OncoDaily selected the most important posts from Day 3 of ASCO24 that you should not miss.
Investing in the next generation of oncologists is crucial for the future of cancer research. At ASCO24, let’s continue to support and mentor young talents who will drive innovation and breakthroughs in oncology. Together, we can achieve more!
We are overwhelmed with support and love and more importantly, excitement about working together to take our recommendations forward from The Lancet Commission on Women, Power, and Cancer!
Special thanks to the American Society of Clinical Oncology (ASCO), Dr. Julie Gralow whose unwavering support and wise counsel helped move this forward – and ASCO President Dr. Lynn Schucter who came to our African launch in Senegal and invited us to contribute to a session at this year’s ASCO event in Chicago.
Women lifting up women – this is the way it’s done!
Read the report. Join the movement.
Not every day that you get to celebrate a years-long survival advantage in the treatment of small cell lung cancer!
Mind-blowing to see the median overall survival for limited stage SCLC approach the oncologically conventional 5-year milestone at ASCO24.
No difference seen in ablation surgery for small sized liver metastases from colorectal cancer. Even though it’s reserved as a backup to surgery, trial had to be stopped half way since it’s as good as (if now lower morbidity). Collision trial at ASCO24.
Much work to be done to understand better how to best use ctDNA in breast cancer but progress is being made. Wonderful co chairing the Bernard Fisher Symposium on the topic in ASCO24.
Today marks my first oral lecture at the Annual Meeting of the American Society of Clinical Oncology (ASCO).
I had the pleasure to present the preliminary results of our ONCOTRUST-1 study at this prestigious meeting.
Thanks to the American Society of Clinical Oncology (ASCO) and Conquer Cancer, the ASCO Foundation for their support to bring researchers from Africa to discuss the global oncology issues in our daily practice and research and to my mentors and collaborators!
Can’t wait for ONCOTRUST-2 study and ASCO25.
Brilliant presentation and work led by Soki Kashima.
- Single-cell analysis can inform outcomes
- CD8 exhausted T cells exhibit programs that are associated with differential outcomes to ICIs in mRCC
- Tissue resident and stress response programs should be further explored.
I had take a quick picture with Zainab Shinkafi-Bagudu before she heads to her busy schedules at ASCO24. Truly, Knowledge Conquers Cancer.
Over 40,000 clinicians, patients and advocates are here exchanging knowledge on the science and art of cancer.
Limitations for tele-health incorporation for palliative care for patients with LC:
- Older patients and other patients with limited digital literacy
- Unknown for other languages beyond English and Spanish
- Lack of minorities representation
- Unclear if survival benefit
American Society of Clinical Oncology (ASCO) Regional Councils Meeting at ASCO24. All volunteers helping to make our society more in tune with specific needs of different geographical regions.
There is a lot to learn and synergise between us the beat cancer globally!
Sunday morning at ASCO24! Starting the day with Skip Burris and David R. Spigel. Big day for small cell lung cancer.
Our amazing CSO Dr. Spigel will be presenting at the big plenary!
- LBA5 ADRIATIC: Durva after CRT in LS-SCLC
- Primary OS and PFS
- NCT03703297
- Today’s trials tomorrow’s therapies
Stop by Poster Board 94 at ASCO24 to discuss male breast cancer in Mexico.
Led by our chief med oncology fellow, Sergio Contreras and in collaboration with INSP, we conducted a retrospective cohort study cross-linking reimbursement claims to a national mortality registry.
NADINA trial making history today at ASCO2024 plenary session. Clear superiority of neaodjuvant Ipi+Nivo compared to adjuvant Nivo in stage III resectable melanoma. EFS as presented today below.
Also, just out full article in NEJM. Very important finding for melanoma patients where new standard of care of two cycles of neoadjuvant immunotherapy treatment will deliver outstanding benefit while allowing avoidance of toxicities under old approach of long term adjuvant therapy.
Results are certainly prompting questions about applicability to adjuvant approach in other tumor indications as well as further fostering debate about neoadjuvant vs adjuvant contribution when two regimens are combined.
Enjoyed discussing the data on AZA-RUX in myelofibrosis in an interview with OncoDaily. Stay tuned for the interview and join me at poster board 131 tomorrow June 3 at 9am!
SCRI Oncology Partner, Dr David Spigel delivers the best science of the ASCO Plenary and receives a standing ovation from the audience. Bringing cutting edge therapies to patients.
